أخبار السوق

تابع أحدث الأخبار المالية والاقتصادية وتحديثات الأسواق والتقارير والتحليلات على PipVero.

المصدر: GlobeNewsWire وكالة أنباء
قبل شهر واحد
الأسهم أهمية متوسطة
Hagens Berman Sobol Shapiro LLP Notifies Shareholders of Photronics, Inc. (PLAB) of a Securities Class Action Lawsuit and the Opportunity to Seek a Lead Plaintiff Position

Hagens Berman Sobol Shapiro LLP Notifies Shareholders of Photronics, Inc. (PLAB) of a Securities Class Action Lawsuit and the Opportunity to Seek a Lead Plaintiff Position

SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a leading national shareholder rights law firm, is conducting an investigation into Photronics, Inc. (NASDAQ: PLAB) regarding alleged violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit, which alleges that Photronics misled investors concerning the demand and outlook for its high-end integrated circuit (IC) photomask product line.

الرموز ذات الصلة 1
PLAB PLAB
المصدر: GlobeNewsWire
زيارة المصدر
Official Partner ITBFX Start Trading
0 0 0
قراءة المزيد
تعليق
المصدر: Seeking Alpha وكالة أنباء
قبل شهر واحد
الأسهم أهمية متوسطة
Dine Brands Global Is Cheap, But The Long-Term Picture Isn't Worth Banking On Yet

Dine Brands Global Is Cheap, But The Long-Term Picture Isn't Worth Banking On Yet

Dine Brands Global reported Q2 2026 revenue above expectations, but EPS and adjusted EPS missed analyst estimates. While DIN remains objectively cheap on both absolute and relative valuation, persistent declines in profitability and rising net debt temper enthusiasm. Growth in IHOP system-wide sales and dual-branded locations offers long-term opportunity, but near-term cash flow and margin pressures persist.

الرموز ذات الصلة 1
GTLL GTLL
المصدر: Seeking Alpha
زيارة المصدر
0 0 0
قراءة المزيد
تعليق
المصدر: Seeking Alpha وكالة أنباء
قبل شهر واحد
الأسهم أهمية متوسطة
Bed Bath & Beyond: An Unprecedented, Unfocused Plan

Bed Bath & Beyond: An Unprecedented, Unfocused Plan

Bed Bath & Beyond, soon Neighborhood Intelligence, is a qualitative turnaround bet centered on CEO Marcus Lemonis's ambitious multi-pillar strategy. Lemonis envisions a synergistic ecosystem spanning retail, financial, and home services, but customer retention and cross-sell logic remain unproven and historically fraught. The investment case is highly speculative; the grand strategy and basic turnaround both face daunting execution risks with little evidence of early traction.

الرموز ذات الصلة 1
BBBY BBBY
المصدر: Seeking Alpha
زيارة المصدر
0 0 0
قراءة المزيد
تعليق
المصدر: WSJ وكالة أنباء
قبل شهر واحد
الأسهم أهمية متوسطة
Alibaba-Backed AI Startup Vast Seeks Fresh Capital, Eyes IPO

Alibaba-Backed AI Startup Vast Seeks Fresh Capital, Eyes IPO

Vast, a Chinese artificial-intelligence unicorn backed by technology titans Alibaba and Baidu, is in talks with investors to get fresh capital, people familiar with the matter say.

الرموز ذات الصلة 1
BABA BABA
المصدر: WSJ
زيارة المصدر
0 0 0
قراءة المزيد
تعليق
المصدر: PRNewsWire وكالة أنباء
قبل شهر واحد
الأسهم أهمية متوسطة
Taboola Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Taboola (TBLA)

Taboola Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Taboola (TBLA)

Taboola told investors its quarter was strong and raised its full-year ex-TAC gross profit outlook. The same release cut 2026 revenue and non-GAAP net income guidance -- and the stock fell.

الرموز ذات الصلة 1
TBLA TBLA
المصدر: PRNewsWire
زيارة المصدر
0 0 0
قراءة المزيد
تعليق
المصدر: MarketBeat وكالة أنباء
قبل شهر واحد
الأسهم أهمية متوسطة
Exelixis Q2 Earnings Call Highlights

Exelixis Q2 Earnings Call Highlights

Exelixis NASDAQ: EXEL reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential late-year launch of zanzalintinib in colorectal cancer and advanced a broader development program for the drug candidate.

الرموز ذات الصلة 1
EXEL EXEL
المصدر: MarketBeat
زيارة المصدر
0 0 0
قراءة المزيد
تعليق
المصدر: Seeking Alpha وكالة أنباء
قبل شهر واحد
الأسهم أهمية متوسطة
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth from Tavalisse and Rezlidhia, offsetting Gavreto's middling performance. RIGL guides $285M–$295M 2026 revenues, excluding Veppanu upside. Upcoming R289 phase 1b data for LR-MDS and future readouts from Veppanu and Rezlidhia trials provide additional growth catalysts.

الرموز ذات الصلة 1
RIGL RIGL
المصدر: Seeking Alpha
زيارة المصدر
Official Partner ITBFX Start Trading
0 0 0
قراءة المزيد
تعليق
المصدر: Reuters وكالة أنباء
قبل شهر واحد
الأسهم أهمية متوسطة
Australia's Beach Energy swings to annual profit, shares slide on weak production outlook

Australia's Beach Energy swings to annual profit, shares slide on weak production outlook

Beach Energy posted an annual profit on Thursday, a sharp turnaround from a year-earlier loss, although ​shares of the Australian oil and gas producer slipped more than 6% as ‌investors focused on its soft production outlook.

الرموز ذات الصلة 1
BCHEY BCHEY
المصدر: Reuters
زيارة المصدر
0 0 0
قراءة المزيد
تعليق
المصدر: Accesswire وكالة أنباء
قبل شهر واحد
الأسهم أهمية متوسطة
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA / ACCESS Newswire / August 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows unanimous recommendations from the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) supporting mFLUSIVA for adults 50 years of age and older.

الرموز ذات الصلة 1
MRNA MRNA
المصدر: Accesswire
زيارة المصدر
0 0 0
قراءة المزيد
تعليق